[A multi-centre study of reproterol, a bronchodilator (author's transl)].
Reproterol (Bronchospasmin), a monomolecular combination of catecholamine and theophylline, was tested in 81 patients with bronchial asthma or chronic obstructive bronchitis after a single oral dose, and compared with orciprenaline by intra-individual cross-over test. Five pulmonary-function laboratories cooperated in the study. A statistically significant bronchodilator effect, as measured by airway resistance and volume-corrected resistance, was obtained with 20 mg reproterol, having its onset after about 30 minutes, reaching its peak after 2-3 hours, and lasting for at least 4 hours. Comparing the area under the time-effect curves, the total effect was greater than that after 20 mg orciprenaline, pO2 rose higher after reproterol than after orciprenaline, but only by a few mm Hg. Neither heart rate nor blood pressure changed significantly after reproterol.
D000403:Airway Resistance; D001249:Asthma / Q000188:drug therapy*; D001794:Blood Pressure; D001991:Bronchitis / Q000188:drug therapy*; D004338:Drug Combinations; D004341:Drug Evaluation; D005260:Female; D006339:Heart Rate; D006801:Humans; D008297:Male; D009921:Metaproterenol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008875:Middle Aged; D010100:Oxygen / Q000097:blood; D010313:Partial Pressure; D013806:Theophylline / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013997:Time Factors
D004338:Drug Combinations; C014792:reproterol; D009921:Metaproterenol; D013806:Theophylline; D010100:Oxygen
Ergebnisse einer multizentrischen Prüfung des Bronchospasmolytikums Reproterol